

See Below for Embargo Dates

Pfizer Oncology Data Presentations at ASCO 2013

At the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting, Pfizer Oncology will present the following data:

Axitinib:

(Abstract #4572) General Poster Session: Prognostic significance of bone metastases (BM) and bisphosphonate (BIS) therapy in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents (MTAs). Rana R. McKay. Monday, June 3. Session Time: 8:00am – 11:45am CDT, Session Location: S Hall A2. *(Embargoed until Wednesday, May 15, 2013 at 6:00pm EDT)*

(Abstract #2533) General Poster Session: Phase Ib safety trial of CVX-060, an intravenous humanized monoclonal CovX body inhibiting angiopoietin 2 (Ang-2), with axitinib in patients with previously treated metastatic renal cell cancer (RCC). Ashwin Gollerkeri. Monday, June 3. Session Time: 8:00am – 11:45am CDT, Session Location: S Hall A2. *(Embargoed until Wednesday, May 15, 2013 at 6:00pm EDT)*

Bosutinib:

(Abstract #7099) General Poster Session: Evolution of bosutinib (BOS) toxicity in patients (pts) with Ph+ leukemia after resistance/intolerance to prior therapy. Carlo Gambacorti-Passerini. Sunday, June 2. Session Time: 8:00am – 11:45am CDT, Session Location: S Hall A2. *(Embargoed until Wednesday, May 15, 2013 at 6:00pm EDT)*

Crizotinib:

(Abstract #8105) General Poster Session: Subgroup analysis of crizotinib versus either pemetrexed (PEM) or docetaxel (DOC) in the phase III study (PROFILE 1007) of advanced ALK-positive non-small cell lung cancer (NSCLC). Benjamin J. Solomon. Saturday, June 1. Session Time: 8:00am – 11:45am CDT, Session Location: S Hall A2. *(Embargoed until Wednesday, May 15, 2013 at 6:00pm EDT)*

(Abstract #8108) General Poster Session: Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced ALK+ non-small cell lung cancer (NSCLC). Vera Hirsh. Saturday, June 1. Session Time: 8:00am – 11:45am CDT, Session Location: S Hall A2. *(Embargoed until Wednesday, May 15, 2013 at 6:00pm EDT)*

(Abstract #8032) Poster Discussion Session: Efficacy and safety of crizotinib in patients with advanced ROS1-rearranged non-small cell lung cancer (NSCLC). Sai-Hong I. Ou. Sunday, June 2. Session Time: 8:00am – 12:00pm CDT, Session Location: E450b. Discussion Time: 11:30am – 12:30pm. Discussion Location: E Hall D2. Poster Board: #21. *(Embargoed until Wednesday, May 15, 2013 at 6:00pm EDT)*

Dacomitinib (PF-00299804):

(Abstract #6041) General Poster Session: Evaluation of potential predictive markers of efficacy of dacomitinib in patients (pts) with recurrent/metastatic SCCHN from a phase II trial. Marie-Lise Audeț. Saturday, June 1. Session Time: 8:00am – 11:45am CDT, Session Location: S Hall A2. *(Embargoed until Wednesday, May 15, 2013 at 6:00pm EDT)*

See Below for Embargo Dates

(Abstract #TPS8123) General Poster Session: Phase III randomized, open label study (ARCHER 1050) of first-line dacomitinib (D) versus gefitinib (G) for advanced (adv) non-small cell lung cancer (NSCLC) in patients (pts) with epidermal growth factor receptor (EGFR) activating mutation(s). Tony Mok. Saturday, June 1. Session Time: 8:00am – 11:45am CDT, Session Location: S Hall A2. *(Embargoed until Wednesday, May 15, 2013 at 6:00pm EDT)*

(Abstract #2568) General Poster Session: Influence of mild and moderate hepatic impairment on the pharmacokinetics (PK) of the pan-HER inhibitor dacomitinib. Nagdeep Giri. Monday, June 3. Session Time: 8:00am – 11:45am CDT, Session Location: S Hall A2. *(Embargoed until Wednesday, May 15, 2013 at 6:00pm EDT)*

Inotuzumab Ozogamicin:

(Abstract #2574) General Poster Session: Phase I study of inotuzumab ozogamicin (INO) combined with R-GDP for relapsed CD22+ B-cell non-Hodgkin lymphoma (B-NHL). Randeep S. Sangha. Monday, June 3. Session Time: 8:00am – 11:45am CDT, Session Location: S Hall A2. *(Embargoed until Wednesday, May 15, 2013 at 6:00pm EDT)*

Palbociclib (PD-0332991):

(Abstract #TPS652) General Poster Session: A randomized, multicenter, double-blind phase III study of palbociclib (PD-0332991), an oral CDK 4/6 inhibitor, plus letrozole versus placebo plus letrozole for the treatment of postmenopausal women with ER(+), HER2(-) breast cancer who have not received any prior systemic anticancer treatment for advanced disease. Richard S. Finn. Saturday, June 1. Session Time: 1:15pm – 5:00pm CDT, Session Location: S Hall A2. *(Embargoed until Wednesday, May 15, 2013 at 6:00pm EDT)*

Sunitinib:

(Abstract #10547) General Poster Session: The influence of gastrointestinal resection on sunitinib exposure in GIST patients. Djoeka de Wit. Saturday, June 1. Session Time: 1:15pm – 5:00pm CDT, Session Location: S Hall A2. *(Embargoed until Wednesday, May 15, 2013 at 6:00pm EDT)*

Early Development Compounds:

(Abstract #4121) General Poster Session: Phase I study of PF-03446962 (anti-ALK-1 mAb) in hepatocellular carcinoma (HCC). Matteo Simonelli. Sunday, June 2. Session Time: 8:00am – 11:45am CDT, Session Location: S Hall A2. *(Embargoed until Wednesday, May 15, 2013 at 6:00pm EDT)*

(Abstract #11031) General Poster Session: Phase I study (A8471004) in Asian patients of PF-03446962, a fully human mab against ALK-1 receptor involved in tumor angiogenesis: Safety, pharmacokinetics (PK), and pharmacodynamics (PD). Kyung-Hun Lee. Monday, June 3. Session Time: 1:15pm – 5:00pm CDT, Session Location: S Hall A2. *(Embargoed until Wednesday, May 15, 2013 at 6:00pm EDT)*



See Below for Embargo Dates

Biosimilars Under Development:

(Abstract #612) General Poster Session: A phase I pharmacokinetics trial comparing PF-05280014 (a potential biosimilar) and trastuzumab in healthy volunteers (REFLECTIONS B327-01). Donghua Yin. Saturday, June 1. Session Time: 1:15pm – 5:00pm CDT, Session Location: S Hall A2. *(Embargoed until Wednesday, May 15, 2013 at 6:00pm EDT)*

###